Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 1999

View Archived Issues

Study results presented for ViroPharma's antiviral agent pleconaril

Angiotech presents positive results from phase I/II MS study

Exisulind leads to lower PSA levels according to interim phase II/III data

Licensing opportunity from Stanford University: treatment of autoimmune disorders

Ligand confirms that ECOG has initiated multicenter phase II study of Ontak for NHL

Gliatech files IDE for ADCON-A antiadhesion barrier

PathoGenesis launches TOBI in second market

Company Profile: Onconova Therapeutics

Inspire presents positive results for dry eye disease therapeutic

Antibody-gold cluster conjugates with broad potential application available for licensing

Duramed's conjugated estrogens now available in U.S.

Novo Nordisk presents new insulin delivery system

New selective 5-HT1B receptor antagonists disclosed by Astra (AstraZeneca)

Magainin: Annual Report 1998

Triangle, Glaxo Wellcome and Emory University resolve emtricitabine dispute

Carbapenems from Merck particularly active against methicillin-resistant Gram-positive pathogens

P&G presents new antimicrobial agents with broad spectrum, including resistant bacteria

CETP inhibitors in the Bayer pipeline

Thrombin inhibitors developed by Merck scientists

Second COX-2 inhibitor reaches the market

Cartilage-derived angiogenesis inhibitor is potentially useful in treating proliferative retinopathy

New benzazepine compound selectively inhibits vitronectin receptors

Spanish team develops microsphere delivery system for improved intravitreal use of corticosteroids

Solvay expands cardiovascular product portfolio

European Union approval obtained for Schering-Plough's combination HCV therapy

CoCensys sells holdings in Cytovia

Sunrise Technologies' hyperopia treatment system scheduled for FDA advisory panel review

Enbrel warning related to infections issued by FDA and Immunex

Oral creatine is neuroprotective in transgenic mouse model of ALS

Brain COX-2 expression and arteriolar vasodilatation in response to inflammatory stimuli

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...